Thank you very much, John, and hello, everyone, and welcome to today's call. As part of our ongoing commitments to transparency, we continue to hold these semiannual investor calls to keep the investment community apprised of our activities. We value this regular opportunity to provide you with insights into our progress and strategic direction. In the first half of 2024, we've made significant progress in executing our business model shift that began a year ago. Our new approach focuses on two key revenue streams, selling our 3D printers in association services and selling our meat and fish premix blends to businesses in foodservice industry. This piece was towards the B2B approach has yielded impressive results. We are proud in the first half of the year to have successfully inked our first recurring revenue strategic agreement, a milestone that was swiftly followed by three similar agreements. Importantly, we achieved these agreements while reducing our operating expenses by more than 50%, largely due to the completion of the major phase of our R&D work. This rapid succession of deals coupled with a reduction in expenses as we move from development to commercialization not only validates our new business direction, but also establishes solid foundation, sustainable profitable growth. Now I'd like to highlight the four commercialization agreements we've secured to date. These agreements represent significant milestones in our growth strategy and demonstrate the market's receptiveness to our innovative solutions. While it's still early in the implementation phase, we're excited about the potential of these agreements hold. Based on our projections and the scale of our partners operations, we believe these deals have the potential to drive substantial recurring revenue growth beginning in 2025. Moreover, they serve as powerful proof points that we can leverage to attract additional partners and expand our market presence. Let's begin with our first agreement, which we've inked with Wyler Farm, leading alternative protein producer, a premier tofu manufacturer in Israel. It's multimillion dollar agreement initially signed in February and since evolved and expanded. In May this year, we signed our first Commercial Cooperation Agreement with Wyler Farm marking our official transition from the R&D stage to the commercialization stage. Wyler Farm will manufacture alternative proteins on a commercial scale using our Steakholder Food beef premix blend and proprietary know-how paying us royalties on sales and they will manage the production process to ensure product quality and the integration of our advanced production technologies, while leveraging their market influence to make the products available at a wide range of sale points. Production of these new plant based products is set to begin in the coming months with initial commercial revenue expected by the end of this year, early next year. Looking ahead, we're in active negotiations for follow on deals for Wyler Farm to produce plant based 3D printed meat products utilizing our proprietary 3D printing technology and premix blends, including production of our flagship printed marbled beefsteak products. Our second key agreement was with Industrial Technology Research Institute, ITRI, a world-leading Applied Technology Research Institute based in Taiwan. This partnership agreement marks a significant step in our global expansion strategy and showcase the versatility of our technology. The core of the agreement is to develop and commercialize a range of food products, specifically tailored for the Taiwanese cuisine, utilizing our advanced 3D printing technology and plant based premixes. To accelerate expansion across Taiwan, we're focusing on commercializing our products through collaboration with leading food companies in the region. A key part of this strategy involves the sale of our commercial scale 3D printers and premixes to these commercial partners. Importantly, this partnership underscores our strategy of collaborating with partners with strong R&D capabilities. By leveraging ITRI's research power, we can continue to innovate while maintaining a lean operational structure. By combining our pioneering 3D printing technology with ITRI's regional consumer insights and local operation, we're well positioned to introduce alternative meats as a sustainable and the locally sourced protein option for the Taiwanese consumers. This partnership not only validates our technology but also demonstrates our ability to adapt to diverse culinary traditions and consumer preferences, while maintaining a cost effective approach to innovation and growth. Building on the momentum from our partners with Wyler Farm, sorry, from our partnerships with Wyler Farm and ITRI. I'm excited to discuss the third significant agreement which we secured back in June with Sherry Herring, a gourmet fish delicacies brand. We signed an MAU to establish a strategic partnership with Sherry Herring to unveil a new line of vegan fish salads developed with the company's proprietary Steakholder Foods SH - Fish premix blends. The collaboration will leverage Sherry Herring's regional expertise and brand recognition to expand our geographical footprint and consumer base and further bolster our growing product portfolio. Capitalizing on Sherry Herring's well established distribution networks spanning delis and restaurants, this new vegan fish salad line will roll out to Sherry Herring's current channel as well as new locations. And lastly, our last agreement in August this year with Premazon, a renowned frozen food manufacturer and institutional distribution. Through this partnership, Premazon will integrate our innovative SH - Fish premix blend into a new plant based white fish kebab line to be made commercially available through Premazon's manufacturing capabilities and distribution network. Premazon currently produces and distributes its products across Israel selling into hotels, restaurants, catering services and other foodservices establishment. This strategic partnership will leverage Premazon's established distribution network introducing a new line of plant based white fish kebabs to these diverse channels in the Israeli market. Shifting to the financial front, I'm pleased to report progress in receiving front on the $1 million grant awarded to us last year by the Singapore-Israel Industrial R&D Foundation. In March of this year, we received our first payment of $220,000. This infusion of non-dilutive capital not only strengthens our financial position, but plays an important role in supporting our innovative work in the alternative protein space and helps us to maintain a trajectory of growth. As we turn the corner into the latter half of this year, our sites are set on three key objectives clinching more commercial deals to broaden our market footprint, supporting our current clients and rolling out the first product to the market and rolling out an expanded suite of product application. The groundwork we've laid to-date through strategic agreements and technological breakthrough serve as a springboard for our future expansion and market penetration. As we progress through the initial phases of our commercial operations and products rollouts, we anticipate modest revenue generation to commence in late 2024 or early 2025. Looking forward ahead, we project accelerated revenue growth in 2025. This anticipated uptick is supported by our progress towards finalizing a global commercial agreement, which we hope to announce by early 2025 as well as the continued expansion of our commercial activities and full implementation. I'm now going to turn it over to our VP Finance, Moran Attar.